Fresenius Kabi looks set to wait until the middle of the next decade to launch its proposed US generic version of Heron Therapeutics’ Cinvanti (aprepitant) injectable emulsion for chemotherapy-induced nausea and vomiting, after falling to the originator in patent-infringement proceedings.
The US District Court for the District of Delaware has held that Kabi’s aprepitant abbreviated new drug application product infringes Heron’s US patents 9,561,229 and 9,974,794, which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?